JP2017506237A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506237A5
JP2017506237A5 JP2016551851A JP2016551851A JP2017506237A5 JP 2017506237 A5 JP2017506237 A5 JP 2017506237A5 JP 2016551851 A JP2016551851 A JP 2016551851A JP 2016551851 A JP2016551851 A JP 2016551851A JP 2017506237 A5 JP2017506237 A5 JP 2017506237A5
Authority
JP
Japan
Prior art keywords
dimethyl
tetrahydropyridin
trifluoro
amino
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506237A (ja
JP6483146B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053327 external-priority patent/WO2015124576A1/en
Publication of JP2017506237A publication Critical patent/JP2017506237A/ja
Publication of JP2017506237A5 publication Critical patent/JP2017506237A5/ja
Application granted granted Critical
Publication of JP6483146B2 publication Critical patent/JP6483146B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016551851A 2014-02-19 2015-02-17 アルツハイマー病治療用のbace1阻害剤としての2−アミノ−3,5,5−トリフルオロ−3,4,5,6−テトラヒドロピリジン Expired - Fee Related JP6483146B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201400086 2014-02-19
DKPA201400086 2014-02-19
DKPA201400349 2014-07-01
DKPA201400349 2014-07-01
PCT/EP2015/053327 WO2015124576A1 (en) 2014-02-19 2015-02-17 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2017506237A JP2017506237A (ja) 2017-03-02
JP2017506237A5 true JP2017506237A5 (enExample) 2018-03-29
JP6483146B2 JP6483146B2 (ja) 2019-03-13

Family

ID=59009438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551851A Expired - Fee Related JP6483146B2 (ja) 2014-02-19 2015-02-17 アルツハイマー病治療用のbace1阻害剤としての2−アミノ−3,5,5−トリフルオロ−3,4,5,6−テトラヒドロピリジン

Country Status (25)

Country Link
US (2) US20170066741A1 (enExample)
EP (1) EP3107897A1 (enExample)
JP (1) JP6483146B2 (enExample)
KR (1) KR20160115936A (enExample)
CN (1) CN106029639B (enExample)
AP (1) AP2016009370A0 (enExample)
AR (1) AR099489A1 (enExample)
AU (1) AU2015220873A1 (enExample)
CA (1) CA2940028A1 (enExample)
CL (1) CL2016002072A1 (enExample)
CR (1) CR20160352A (enExample)
DO (1) DOP2016000194A (enExample)
EA (1) EA031132B1 (enExample)
EC (1) ECSP16072941A (enExample)
GE (1) GEP20186892B (enExample)
IL (1) IL246875A0 (enExample)
MA (1) MA39225A1 (enExample)
MX (1) MX2016010777A (enExample)
PE (1) PE20161225A1 (enExample)
PH (1) PH12016501600A1 (enExample)
RU (1) RU2016133626A (enExample)
SG (1) SG11201606812WA (enExample)
TW (1) TW201609700A (enExample)
UA (1) UA117695C2 (enExample)
WO (1) WO2015124576A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161225A1 (es) 2014-02-19 2016-12-04 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) * 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療
WO2017025559A1 (en) * 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
EP3347486A4 (en) * 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
TW201726651A (zh) * 2015-09-23 2017-08-01 健生藥品公司 2,3,4,5-四氫吡啶-6-胺衍生物
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP2020500841A (ja) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノンの投与を含む併用療法
EP3532064B1 (en) 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
TW201829394A (zh) 2016-12-21 2018-08-16 丹麥商H 朗德貝克公司 作為bace1抑制劑之6-胺基-5-氟-5-(氟甲基)-2,3,4,5-四氫吡啶-2-基-苯基-5-(甲氧基-d)-吡-2-甲醯胺及其氟化衍生物
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111465410B (zh) 2017-12-14 2022-10-25 H.隆德贝克有限公司 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
EP3728250A1 (en) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS
KR102507861B1 (ko) 2018-04-19 2023-03-09 삼성에스디에스 주식회사 부채널 공격에 안전한 연산 장치 및 방법
KR102510077B1 (ko) 2018-04-24 2023-03-14 삼성에스디에스 주식회사 부채널 공격에 안전한 연산 장치 및 방법
US12042492B2 (en) 2020-10-09 2024-07-23 Texas Tech University System BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
GB0124928D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003068747A1 (en) * 2002-02-12 2003-08-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
WO2011154431A1 (en) * 2010-06-09 2011-12-15 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
WO2012057248A1 (ja) * 2010-10-29 2012-05-03 塩野義製薬株式会社 ナフチリジン誘導体
US20130281449A1 (en) 2011-01-12 2013-10-24 Novartis Ag Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
PL2663561T3 (pl) 2011-01-13 2016-10-31 Nowe pochodne heterocykliczne i ich zastosowanie w leczeniu zaburzeń neurologicznych
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
JPWO2012147763A1 (ja) * 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
BR112013031098A2 (pt) * 2011-06-07 2016-12-06 Hoffmann La Roche halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
UY34278A (es) * 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
US8338413B1 (en) * 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US9493485B2 (en) 2012-03-20 2016-11-15 Imago Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
TW201446758A (zh) 2013-03-01 2014-12-16 Amgen Inc 作爲β-分泌酶抑制劑的全氟化5,6-二氫-4H-1,3-□-2-胺化合物及其用途
PE20161225A1 (es) 2014-02-19 2016-12-04 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物

Similar Documents

Publication Publication Date Title
JP2017506237A5 (enExample)
RU2016133626A (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2019517455A5 (enExample)
JP2017538750A5 (enExample)
RU2021127810A (ru) Замещенные гетероарилом пиридины и способы применения
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2013539774A5 (enExample)
RU2501791C2 (ru) Производное триазола или его соль
JP2015509510A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
JP2012530705A5 (enExample)
JP2013519680A5 (enExample)
JP2011500679A5 (enExample)
JP2016540811A5 (enExample)
JP2016534124A5 (enExample)
JP2016523963A5 (enExample)
JP2005517006A5 (enExample)
RU2018143324A (ru) Применение 1H-пиразоло[4,3-b]пиридинов в качестве ингибиторов PDE1
JP2013527847A5 (enExample)
HRP20191554T1 (hr) Derivat azol benzena
RU2015104962A (ru) Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков
JP2017509676A5 (enExample)